Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by Xencor
Vudalimab is an Fc-engineered bispecific antibody that binds both PD-1 and CTLA-4 on tumor-infiltrating T lymphocytes, blocking their inhibitory signaling to restore T-cell activation and proliferation. It is being studied in ovarian, endometrial, cervical and biliary tract cancers, clear cell carcinoma, and metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05032040 | Phase 2 | Ovarian Cancer | Active not recruiting | XNCR |
| NCT05297903 | Phase 2 | Biliary Tract Cancer | Completed | XNCR |
| NCT05005728 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cervical CarcinomaClear Cell CarcinomaEndometrial CancerMetastatic Castration-Resistant Prostate Cancer (mCRPC)Ovarian CancerBiliary Tract CancerMetastatic Castration-Resistant Prostate Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →